BridgeMD
New treatment option for IBS
Official title Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
ClinicalTrials.gov ID: NCT02421705
What this study is testing
- What it's testing
- Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65. Healthy volunteers may be eligible.
You may be able to join if
- For group 1: IBS
- Irritable Bowel Syndrome (IBS) (ROME III criteria)
- No obvious organic explanation for the IBS symptoms
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Group 2: active ulcerative...
- diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
You likely can't join if
- For all groups:
- co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting
- Abdominal chirurgy (except for an uncomplicated appendectomy)
See the full eligibility criteria
- For group 1: IBS
- Irritable Bowel Syndrome (IBS) (ROME III criteria)
- No obvious organic explanation for the IBS symptoms
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one...
- diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
- remission is confirmed by at least one sigmoidoscopy
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Only for group 3a:
- Rome III criteria for IBS Group 4: Healthy controls No abdominal (pain) complaints. Group 5: active Crohn's disease 1\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects...
- diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
- remission is confirmed by at least one sigmoidoscopy
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
- For all groups:
- co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting
- Abdominal chirurgy (except for an uncomplicated appendectomy)
The study team makes the final eligibility decision.
Where it's taking place
- Leuven, Vlaams-Brabant, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Leuven, Vlaams-Brabant, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.